Med Spa & Aesthetic Medicine Fraud Defense
Former DOJ Fraud Section Prosecutors. Nationwide Defense for Med Spa Owners, Aesthetic Practitioners, IV Therapy Clinic Operators, Physicians, and Healthcare Executives Facing FDA Investigations, DOJ Prosecutions, and State Enforcement Actions Involving Counterfeit Injectables, Botox Fraud, Unapproved Aesthetic Products, and Healthcare Billing Fraud.
Based in Washington, D.C., Armstrong & Bradylyons PLLC defends med spa owners, aesthetic practitioners, nurse injectors, dermatologists, plastic surgeons, IV therapy clinic operators, aestheticians, and healthcare executives in federal and state investigations and prosecutions involving the sale, administration, and billing of Botox, dermal fillers, aesthetic injectables, IV infusion therapies, and other med spa services.
The med spa and aesthetic medicine industry is under unprecedented enforcement pressure. In December 2025, DOJ indicted a California physician for orchestrating a $45 million Botox fraud scheme targeting Medicare. The case was identified through DOJ’s Health Care Fraud Data Analytics Team, which detected billing anomalies at the physician’s facility. That same month, a Massachusetts med spa owner agreed to plead guilty to injecting clients with unapproved botulinum toxin imported from overseas, causing 10 botulism cases. In January 2025, a Manhattan aesthetician was arrested for importing and injecting counterfeit Botox from China, causing hospitalizations. In November 2025, the FDA sent warning letters to 18 cosmetic websites for illegally marketing counterfeit or unapproved Botox and similar injectables. A Virginia defendant faced 34 federal counts for selling non-FDA-approved cosmetic devices and unapproved drugs. The enforcement is accelerating from every direction.
The firm’s healthcare fraud defense practice is built on nearly a decade of combined experience at DOJ’s Fraud Section. Scott Armstrong, Drew Bradylyons, and Andrea Savdie tried 17 federal jury trials in healthcare fraud cases at DOJ involving over $2.8 billion in alleged false and fraudulent claims. DOJ’s Health and Safety Unit, created in November 2025, now handles criminal FDCA prosecutions involving counterfeit and unapproved medical products. The firm defends individuals in the same enforcement actions that the Fraud Section brings against med spa operators.
Armstrong & Bradylyons PLLC defends every med spa and aesthetic medicine enforcement matter from the start as if it will proceed to criminal prosecution. Med spa enforcement has crossed from regulatory territory into federal criminal prosecution. The firm prepares accordingly.
Med spa enforcement converges multiple enforcement vectors the firm already defends. Counterfeit injectable prosecutions involve FDCA violations, wire fraud, and smuggling charges. Medicare billing fraud at aesthetic practices involves healthcare fraud and False Claims Act liability. Compounding pharmacies that supply med spas face parallel FDA enforcement. Kickback arrangements between med spas and referral sources trigger Anti-Kickback Statute charges. Scott Armstrong served for nearly a decade at DOJ’s Fraud Section, trying 16 federal jury trials. Drew Bradylyons supervised the Healthcare Fraud Unit’s Miami Strike Force and served as Chief of EDVA’s Financial Crimes Unit. The firm brings the trial and prosecution experience that med spa enforcement demands.
Med spa enforcement is intensifying across every enforcement agency. DOJ, the FDA, HHS-OIG, the FTC, U.S. Customs and Border Protection, and state medical boards are all targeting med spas through distinct but overlapping enforcement actions.
DOJ Criminal Prosecutions
In December 2025, DOJ indicted a Glendale, California physician for orchestrating a $45 million Medicare fraud scheme involving Botox injections. The indictment alleged billing for Botox treatments that were medically unnecessary or never provided, including on dates when the clinic was closed, when the physician was traveling abroad, and when patients were incarcerated. The investigation was driven by DOJ’s Health Care Fraud Data Analytics Team, which identified billing anomalies. This case illustrates DOJ’s increasing use of data analytics to proactively identify med spa billing fraud.
Counterfeit Injectable Enforcement
Federal prosecutors are aggressively pursuing med spa operators who import and administer counterfeit injectables. In January 2025, a Manhattan aesthetician was arrested for importing counterfeit Botox from China and injecting clients without a license, causing botulism symptoms including double vision, difficulty swallowing, and muscle paralysis. In November 2024, a Massachusetts med spa owner was charged with importing counterfeit Botox, Sculptra, and Juvederm from China and Brazil and performing over 2,700 appointments generating over $900,000, while falsely representing to clients that she was a licensed nurse. In 2024, fake Botox sent at least 13 U.S. residents to the hospital. Customs and Border Protection intercepts counterfeit products at the border. The FDA issued warning letters to 18 cosmetic websites in November 2025 for marketing counterfeit or unapproved Botox.
FDA Enforcement
The FDA targets med spas that administer unapproved products, market products with false therapeutic claims, source products from unlicensed suppliers, or operate compounding operations without compliance with Section 503A or Section 503B of the FDCA. The FDA also targets med spas administering unapproved stem cell and exosome products, unapproved peptides and GLP-1s, and non-FDA-approved aesthetic devices. FDA enforcement actions can escalate to criminal referrals to DOJ.
State Medical Board and Corporate Practice of Medicine Enforcement
State medical boards are pursuing med spa operators for practicing medicine without a license, performing injections without appropriate credentials, operating without adequate physician supervision, and violating corporate practice of medicine laws. Many states prohibit non-physicians from owning medical practices, creating exposure for med spa investors and non-physician owners who employ nurse practitioners or physician assistants to perform procedures under nominal physician supervision. State enforcement runs in parallel with federal investigations.
Defending Against Charges for Importing or Administering Counterfeit Injectables
The government charges med spa operators who import or administer counterfeit Botox, fillers, and other injectables with wire fraud, smuggling, FDCA violations, and conspiracy. The firm defends operators by analyzing the supply chain, challenging the government’s evidence of knowledge that products were counterfeit, demonstrating reliance on supplier representations, and contesting the government’s proof of intent to defraud.
Defending Against Medicare and Insurance Billing Fraud Charges
The government charges healthcare fraud when med spas and aesthetic practices bill Medicare or insurance for Botox, dermal fillers, or other aesthetic treatments that were cosmetic rather than medically necessary, that were not provided, or that were billed at inflated levels. The firm retains clinical experts to establish medical necessity and demonstrates that billing reflected services actually rendered.
Responding to FDA Warning Letters, Inspections, and Criminal Referrals
The firm defends med spas responding to FDA warning letters, Form 483 observations, and criminal referrals involving unapproved products, insanitary conditions, misbranded products, and false marketing claims. The firm develops response strategies to resolve regulatory matters and prevent escalation to criminal prosecution.
Defending Against State Licensing and Corporate Practice of Medicine Violations
The firm defends med spa owners, investors, and practitioners against state medical board investigations and corporate practice of medicine allegations. The firm analyzes ownership structures, physician supervision arrangements, and practitioner credentials to develop defenses and demonstrate compliance with state-specific requirements.
Defense of Med Spa Owners and Operators
The firm defends owners and operators of med spas, aesthetic clinics, IV therapy centers, and cosmetic practices. Owners face criminal exposure for importing counterfeit products, administering unapproved injectables, billing Medicare or insurance for cosmetic services coded as medically necessary, operating without adequate physician supervision, and violating corporate practice of medicine laws.
Defense of Physicians and Medical Directors
The firm defends physicians, dermatologists, plastic surgeons, and medical directors who face charges in connection with med spa operations. Physicians face exposure for billing medically unnecessary Botox or filler treatments to Medicare, serving as absentee medical directors, allowing their credentials to be used by unlicensed staff, or prescribing controlled substances through med spa telehealth platforms. The $45 million Botox indictment in December 2025 demonstrates that DOJ is using data analytics to identify individual physician billing outliers.
Defense of Nurse Injectors and Aesthetic Practitioners
The firm defends nurse practitioners, physician assistants, registered nurses, and aestheticians who face criminal charges or licensing actions for performing procedures beyond their scope of practice, administering unapproved products, or participating in billing schemes. The firm defends practitioners by establishing that their activities were within their scope of licensure and under appropriate physician supervision.
Defense of Product Suppliers and Distributors
The firm defends companies and individuals who supply injectable products, aesthetic devices, and IV therapy products to med spas. Suppliers face FDCA charges, wire fraud, and smuggling charges when the government alleges they distributed counterfeit, unapproved, or misbranded products. The firm defends suppliers by analyzing product sourcing, FDA registration, and labeling compliance.
Defense of Investors and Management Companies
The firm defends investors, private equity sponsors, and management services organizations (MSOs) that own or manage med spa operations. Investors face exposure under theories of conspiracy, aiding and abetting, and corporate practice of medicine violations when the government alleges they directed billing practices, designed compensation structures, or controlled clinical decision-making through non-physician ownership.
Scott Armstrong and Drew Bradylyons built healthcare fraud cases at DOJ’s Fraud Section. They understand how regulatory investigations become criminal referrals.
Data Analytics and Billing Pattern Analysis
DOJ’s Health Care Fraud Data Analytics Team analyzes Medicare and insurance claims data to identify med spas and aesthetic practices with anomalous billing patterns. The $45 million Botox indictment was identified through data analytics. The government flags providers billing disproportionately high volumes of Botox or other injectables, billing on dates when the provider was unavailable, billing patients who do not meet medical necessity criteria, or billing for services at rates inconsistent with peer benchmarks.
Customs Seizures and Import Investigations
U.S. Customs and Border Protection intercepts counterfeit injectables at the border. Seizures of counterfeit Botox, fillers, and aesthetic products imported from China, Brazil, and other countries trigger federal investigations. Customs seizures often lead to criminal referrals to the FDA Office of Criminal Investigations and DOJ.
FDA Warning Letters and Inspections
The FDA issues warning letters to med spas and cosmetic websites marketing counterfeit or unapproved products. The FDA conducts inspections of compounding operations and aesthetic product suppliers. Warning letters are published on the FDA’s website and can escalate to criminal referral.
Undercover Operations and Patient Complaints
Federal and state investigators deploy undercover agents to obtain treatments at targeted med spas. Patient complaints, adverse event reports, and botulism cases trigger investigations. The Matthew Perry investigation and the Massachusetts botulism cluster demonstrate that patient harm events accelerate enforcement dramatically.
State Medical Board and Attorney General Investigations
State medical boards investigate med spa practitioners for scope-of-practice violations, inadequate supervision, and unsubstantiated marketing claims. State attorneys general use consumer protection statutes to pursue deceptive advertising and unlicensed practice. State proceedings run in parallel with federal investigations.
Search Warrants and Electronic Evidence
Federal agents execute search warrants at med spas, residences, and storage facilities. They seize patient records, financial records, product inventory, importation records, cell phones, and computers. They obtain cloud warrants under 18 U.S.C. § 2703 for email, text messages, and social media accounts.
Wire Fraud (18 U.S.C. § 1343)
Wire fraud is the primary charging statute in counterfeit injectable cases. It carries up to 20 years per count. Wire fraud captures online sales, electronic payment processing, social media marketing, and interstate communications in furtherance of the fraud scheme.
Healthcare Fraud (18 U.S.C. § 1347)
Healthcare fraud is charged when med spas bill Medicare or insurance for services not rendered, for cosmetic procedures coded as medically necessary, or for treatments using counterfeit products. Up to 10 years per count. If serious bodily injury results, up to 20 years.
FDCA Violations (21 U.S.C. §§ 331, 333)
Distribution of counterfeit, adulterated, or misbranded drugs and devices violates the FDCA. Misdemeanor violations carry up to one year. Felony violations with intent to defraud carry up to three years, or up to 10 years for second offenses.
Smuggling (18 U.S.C. § 545)
Smuggling is charged when med spa operators import counterfeit products from overseas. Smuggling carries up to 20 years per count. The Manhattan Botox arrest in January 2025 included smuggling charges for importing counterfeit Botox from Asia.
Money Laundering (18 U.S.C. §§ 1956, 1957)
Money laundering carries up to 20 years per count. The government charges money laundering when fraud proceeds are laundered through financial transactions.
Collateral Consequences
Beyond incarceration, a conviction triggers mandatory exclusion from federal healthcare programs, state medical license revocation, DEA registration revocation for practitioners who prescribe controlled substances, product seizure, forfeiture of fraud proceeds, and permanent reputational damage from published FDA warning letters and DOJ press releases.
What Types of Med Spa Fraud Does the Government Prosecute?
Federal prosecutors target importing and administering counterfeit Botox, dermal fillers, and other injectables; billing Medicare or insurance for cosmetic treatments coded as medically necessary; administering unapproved products sourced from unlicensed foreign suppliers; performing injections without proper credentials or physician supervision; billing for Botox or other treatments that were never provided; and marketing med spa services with false or misleading therapeutic claims. The $45 million Medicare Botox indictment in December 2025 and the counterfeit Botox arrests demonstrate the breadth of enforcement.
Can a Med Spa Owner Face Federal Criminal Charges for Counterfeit Botox?
Yes. Federal prosecutors charge med spa operators who import or administer counterfeit injectables with wire fraud (up to 20 years), smuggling (up to 20 years), FDCA violations, and conspiracy. In January 2025, a Manhattan aesthetician was arrested for importing counterfeit Botox from China. A Massachusetts med spa owner faced charges for importing counterfeit Botox, Sculptra, and Juvederm from China and Brazil and performing over 2,700 appointments generating over $900,000. In 2024, fake Botox sent at least 13 U.S. residents to the hospital.
How Does DOJ Use Data Analytics to Identify Med Spa Billing Fraud?
DOJ’s Health Care Fraud Data Analytics Team analyzes Medicare claims data to identify providers with anomalous Botox and injectable billing patterns. In the $45 million December 2025 indictment, DOJ’s data analytics identified that other providers had not billed the same patients for Botox injections and that injections were allegedly administered when the facility was closed. This case was highlighted in DOJ’s 2025 Year in Review as a model for data-driven investigation. Med spas billing Medicare for Botox or other injectables should expect their billing patterns to be compared against national benchmarks.
What Are the Penalties for a Federal Med Spa Fraud Conviction?
Wire fraud carries up to 20 years per count. Smuggling carries up to 20 years per count. Healthcare fraud carries up to 10 years per count. FDCA felony violations carry up to three years, or 10 years for repeat offenses. Beyond incarceration, defendants face federal program exclusion, state license revocation, product seizure, forfeiture, and restitution.
Is Billing Medicare for Botox Legal?
Botox is billable under Medicare only for specific FDA-approved medical conditions, such as chronic migraines, cervical dystonia, spasticity, and overactive bladder, and only after conservative treatments have failed. Billing Medicare for cosmetic Botox is fraud. Claims must be supported by clinical documentation demonstrating medical necessity. The December 2025 indictment alleged billing for patients who did not meet Medicare criteria for Botox treatment and falsifying medical records to fabricate chronic migraine diagnoses.
Can a Non-Physician Med Spa Owner Face Criminal Charges?
Yes. Non-physician med spa owners face criminal exposure for corporate practice of medicine violations, for directing practitioners to perform procedures beyond their scope, for importing counterfeit products, and for designing billing schemes. Both the Manhattan and Massachusetts counterfeit Botox cases involved non-physician operators (aestheticians) who performed injections without appropriate licensure. The firm defends non-physician owners by analyzing state-specific corporate practice of medicine requirements and challenging the government’s evidence of personal direction and intent.
What Is the FDA’s Role in Med Spa Enforcement?
The FDA targets med spas that administer counterfeit, adulterated, or misbranded products. In November 2025, the FDA sent warning letters to 18 cosmetic websites for marketing counterfeit or unapproved Botox. The FDA’s Office of Criminal Investigations investigates med spa operators who import counterfeit products. FDA enforcement actions can escalate to criminal referrals to DOJ. The FDA also targets med spas administering unapproved stem cell products, peptides, and non-FDA-approved aesthetic devices.
Do IV Therapy Clinics Face Federal Enforcement?
Yes. IV therapy clinics face enforcement exposure for billing insurance for elective vitamin infusions coded as medically necessary treatments, for administering unapproved products (NAD+, high-dose vitamin C, glutathione) with unsubstantiated therapeutic claims, for compounding IV formulations without compliance with FDA requirements, and for operating without adequate physician supervision. The FTC targets deceptive advertising claims. The FDA targets unapproved products marketed with therapeutic claims.
What Should a Med Spa Do After Receiving an FDA Warning Letter?
Engage experienced defense counsel immediately. The warning letter requires a written response within 15 business days. Continuing the violating conduct after receiving a warning letter dramatically increases criminal exposure. The firm develops response strategies to resolve regulatory matters and prevent escalation to criminal referral.
Does Armstrong & Bradylyons Handle Med Spa Cases Nationwide?
Yes. Armstrong & Bradylyons PLLC defends individuals and companies in federal and state med spa and aesthetic medicine investigations in every jurisdiction. Enforcement is active nationwide, with significant cases in the Southern District of New York, the District of Massachusetts, the Central District of California, the Eastern District of Virginia, and the Southern District of Florida. Scott Armstrong and Drew Bradylyons have tried healthcare fraud cases in federal courts throughout the country during their combined 25-year DOJ career. The firm is based in Washington, D.C.